Illumina Stock In Focus After New Genomic AI Model Launch
- Illumina introduced SpliceAI2, a genomic AI model that predicts splice effects and identified 17% more disease relevant variants in rare disease research datasets compared with other splicing models.
- The launch expands Illumina's BioInsight AI Lab toolkit alongside PromoterAI and PrimateAI-3D, and it gives researchers broader coverage of splice, promoter, and missense variants while reducing the volume of variants that require manual review.
- We will now see how Illumina's SpliceAI2 launch, with its higher detection of disease relevant splice variants, could shape the investment narrative.
Illumina Investment Narrative Recap
To back Illumina as a shareholder, you need to believe genomic tools and data centric AI models can keep driving demand for sequencing instruments, consumables, and software. SpliceAI2 fits that story by making Illumina's installed base more useful in clinical and research workflows. The bigger swing factor in the near term still looks like execution in clinical genomics, where consumables already dominate.
The key risk remains pressure on funding and competition in core markets, which sits alongside a rich P/E multiple and profit margins that are below last year. SpliceAI2 does not change those constraints on its own. The upcoming Q3 2026 results call on October 29 now matters more as a read on order trends, pricing, and any update on China and research budgets.
Among recent announcements, the Q3 2026 earnings release and call are the most relevant for framing this SpliceAI2 launch. Investors will be looking for management to quantify how the broader BioInsight AI suite, including SpliceAI2, PromoterAI, and PrimateAI 3D, is affecting customer adoption, pull through on consumables, and any early signals in clinical testing workflows.
That event also gives you a checkpoint on execution against the existing narrative. Revenue is forecast to grow 6.6% per year and earnings 12.3% per year, with profit margins expected to improve over time. The combination of a premium valuation and slower forecast growth than the wider US market, together with past margin compression, means commentary around AI driven tools like SpliceAI2 will sit alongside, not replace, questions on funding risk, China exposure, and competitive pressure.
Illumina Forecast Checkpoint After SpliceAI2
Illumina's current analyst narrative ties the SpliceAI2 launch into a bigger financial picture that already assumes steady expansion in genomics. Forecasts point to revenues of $5.5b and earnings of $1.1b by 2029, with profit margins expected to move from 18.3% today to 20.6% over roughly three years. Against that backdrop, SpliceAI2 is another tool that could help Illumina defend those margin and volume assumptions if it deepens usage of sequencing systems in clinical and rare disease settings.
The step up in profitability expectations is not trivial. Consensus calls for earnings to rise from $824.0m today to $1.1b by 2029, which is an increase of about $276m, while analysts also factor in a 1.18% yearly decline in the share count over the next three years. That combination implies higher earnings spread across fewer shares, a setup that could matter for long term holders if it plays out in line with the current models rather than getting reset lower at future earnings updates.
Valuation work in the latest reports anchors on that same 2029 snapshot. To line up with the analyst price targets, you would need to assume Illumina reaches $5.5b in revenue and $1.1b in earnings by 2029 and trades on a P/E of 33.6x, compared with 49.8x today and 41.0x for the wider US life sciences peer group. Those inputs are also discounted using a rate of about 8.2%, which sets the hurdle for how much cash flow Illumina needs to generate to justify a lower future multiple than both its current level and the sector average.
That is where the current share price creates a tension for anyone tracking AI heavy product launches like SpliceAI2. The consensus target sits at $206.65 against a spot price of $272.0, which is about 31.6% lower. Analysts are effectively saying Illumina may be too richly priced even though they model a 7.0% annual revenue growth rate and higher margins over time, so any impact from SpliceAI2 and the broader BioInsight AI suite is being judged inside a framework where the market is already paying up for the story.
Illumina's narrative projects $5.5b revenue and $1.1b earnings by 2029. This assumes 7.0% yearly revenue growth and an earnings increase of about $276m from $824.0m today.
Uncover why Illumina's fair value indicates a 26% potential downside to its current price, which leaves little room for error.
Exploring Other Perspectives
One alternate view focuses less on Illumina’s AI toolkit and more on margin pressure. The most bearish analysts were only modeling about 5.5% yearly revenue growth to roughly US$5.3b by 2029 and earnings of about US$1.1b before SpliceAI2. That group effectively prices in legal, cost, and competition worries much more harshly. These forecasts were set before this launch, so you now get to decide whether SpliceAI2 could nudge your own expectations closer to consensus or toward that more cautious camp.
Explore 3 other Illumina fair value estimates, including one that suggests as much as 26% downside from the current price.
Reach Your Own Conclusion
Don't just follow the ticker, dig into the data and build a conviction that's truly your own.
- A great starting point for your Illumina research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Illumina. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Illumina's overall financial health at a glance.
Looking For More Illumina Investment Ideas?
If Illumina has sharpened your interest in genomics and data driven healthcare, it can help to widen the lens and compare it with other listed businesses. The Simply Wall St Screener gives you a structured way to filter for balance sheet strength, income potential, or mispriced quality so you can see where Illumina fits relative to peers.
- For investors who care most about financial resilience and fundamentals, start with a list of solid balance sheet and fundamentals (25 results) that keep debt and cash flows firmly in check.
- If your priority is mispriced quality, line Illumina up against 20 high quality undiscovered gems that pair solid metrics with relatively low market attention.
- For readers who lean toward stability and income, scan a curated group of 8 dividend fortresses that balance payout strength with underlying business quality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com